
Eradivir
Developer of a novel bispecific immunotherapy platform designed for patients' immune systems to kill both viruses and virus-infected cells. The company offers ligands with high specificity and avidity...
Valuation
$113M
Latest known
Share Price
N/A
Total Raised
$30.1M
Last Round
N/A